Perspectives of biomolecular NMR in drug discovery: the blessing and curse of versatility.
The versatility of NMR and its broad applicability to several stages in the drug discovery process is well known and generally considered one of the major strengths of NMR (Pellecchia et al., Nature Rev Drug Discov 1:211-219, 2002; Stockman and Dalvit, Prog Nucl Magn Reson Spectrosc 41:187-231, 2002; Lepre et al., Comb Chem High throughput screen 5:583-590, 2002; Wyss et al., Curr Opin Drug Discov Devel 5:630-647, 2002; Jahnke and Widmer, Cell Mol Life Sci 61:580-599, 2004; Huth et al., Methods Enzymol 394:549-571, 2005b; Klages et al., Mol Biosyst 2:318-332, 2006; Takeuchi and Wagner, Curr Opin Struct Biol 16:109-117, 2006; Zartler and Shapiro, Curr Pharm Des 12:3963-3972, 2006). Indeed, NMR is the only biophysical technique which can detect and quantify molecular interactions, and at the same time provide detailed structural information with atomic level resolution. NMR should therefore be ideally suited and widely requested as a tool for drug discovery research, and numerous examples of drug discovery projects which have substantially benefited from NMR contributions or were even driven by NMR have been described in the literature. However, not all pharmaceutical companies have rigorously implemented NMR as integral tool of their research processes. Some companies invest with limited resources, and others do not use biomolecular NMR at all. This discrepancy in assessing the value of a technology is striking, and calls for clarification--under which circumstances can NMR provide added value to the drug discovery process? What kind of contributions can NMR make, and how is it implemented and integrated for maximum impact? This perspectives article suggests key areas of impact for NMR, and a model of integrating NMR with other technologies to realize synergies and maximize their value for drug discovery.
Jahnke
Wolfgang
W
Novartis Institutes for BioMedical Research, Discovery Technologies, Basel 4002, Switzerland. wolfgang.jahnke@novartis.com
D015195:Drug Design; D004353:Drug Evaluation, Preclinical / Q000379:methods*; D004345:Drug Industry; D019906:Nuclear Magnetic Resonance, Biomolecular / Q000379:methods*; D012984:Software
Comb Chem High Throughput Screen. 2002 Dec;5(8):583-90
12470255
Angew Chem Int Ed Engl. 2005 Jul 4;44(27):4172-5
15929149
Analyst. 2007 Jul;132(7):693-705
17657909
Nat Rev Drug Discov. 2002 Mar;1(3):211-9
12120505
Science. 1996 Nov 29;274(5292):1531-4
8929414
Curr Opin Struct Biol. 2006 Feb;16(1):109-17
16427776
J Am Chem Soc. 2005 Jan 12;127(1):217-24
15631471
Curr Opin Drug Discov Devel. 2005 Jul;8(4):513-9
16022188
Drug Discov Today. 2003 Sep 1;8(17):803-10
12946643
J Med Chem. 2007 May 3;50(9):2137-43
17394300
Nature. 2005 Jun 2;435(7042):677-81
15902208
Curr Drug Discov Technol. 2006 Jun;3(2):115-24
16925519
Cell Mol Life Sci. 2004 Mar;61(5):580-599
15004697
Chembiochem. 2002 Mar 1;3(2-3):167-73
11921394
J Am Chem Soc. 2004 Mar 3;126(8):2390-8
14982445
Curr Opin Drug Discov Devel. 2002 Jul;5(4):630-47
12197321
Nat Rev Drug Discov. 2007 Mar;6(3):211-9
17290284
Curr Opin Drug Discov Devel. 2007 May;10(3):289-97
17554855
Curr Pharm Des. 2006;12(31):3963-72
17100607
Chemistry. 2006 Mar 20;12(10):2658-62
16121405
Methods Enzymol. 2005;394:549-71
15808237